In Hwan Tae, Yunsang Kang, Jinkwon Lee, Jeongmin Lee, Jinsan Kim, Haneol Yang, Kunhyang Park, Doo-Sang Park, Dae-Soo Kim, Hyun-Soo Cho
{"title":"Apoptosis-Inducing Effects of <i>Lactobacillus plantarum</i> DS0709 in Colorectal Cancer.","authors":"In Hwan Tae, Yunsang Kang, Jinkwon Lee, Jeongmin Lee, Jinsan Kim, Haneol Yang, Kunhyang Park, Doo-Sang Park, Dae-Soo Kim, Hyun-Soo Cho","doi":"10.4014/jmb.2504.04042","DOIUrl":null,"url":null,"abstract":"<p><p>In colorectal cancer (CRC) treatment, various approaches, including chemotherapy (5-FU, irinotecan, and oxaliplatin), targeted therapy (VEGF inhibitor) and immunotherapy (PD-1/ PD-L1 inhibitor), are employed. However, due to side effects and limited efficacy, more effective novel therapeutic strategies have been required. In this study, we identified the anti-cancer effects of <i>Lactobacillus plantarum</i> DS0709, isolated from infant feces, on CRC. Treatment with the supernatant (Sup) of <i>L. plantarum</i> DS0709 demonstrated growth inhibition of CRC cell lines (HCT116 and SNUC5) by inducing apoptosis. Additionally, using human iPSC-derived intestinal organoids (hIO), we confirmed that <i>L. plantarum</i> DS0709 Sup exhibited no toxicity. Furthermore, in a 3D spheroid model mimicking <i>in vivo</i> conditions, <i>L. plantarum</i> DS0709 Sup showed similar apoptosis induction and growth-inhibitory effects as in 2D cultures. Thus, these findings suggest that <i>L. plantarum</i> DS0709 has the potential to be developed into a novel microbiome-based therapeutic agent for CRC, offering anti-cancer efficacy without side effects.</p>","PeriodicalId":16481,"journal":{"name":"Journal of microbiology and biotechnology","volume":"35 ","pages":"e2504042"},"PeriodicalIF":3.1000,"publicationDate":"2025-08-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12375538/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of microbiology and biotechnology","FirstCategoryId":"5","ListUrlMain":"https://doi.org/10.4014/jmb.2504.04042","RegionNum":4,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"BIOTECHNOLOGY & APPLIED MICROBIOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
In colorectal cancer (CRC) treatment, various approaches, including chemotherapy (5-FU, irinotecan, and oxaliplatin), targeted therapy (VEGF inhibitor) and immunotherapy (PD-1/ PD-L1 inhibitor), are employed. However, due to side effects and limited efficacy, more effective novel therapeutic strategies have been required. In this study, we identified the anti-cancer effects of Lactobacillus plantarum DS0709, isolated from infant feces, on CRC. Treatment with the supernatant (Sup) of L. plantarum DS0709 demonstrated growth inhibition of CRC cell lines (HCT116 and SNUC5) by inducing apoptosis. Additionally, using human iPSC-derived intestinal organoids (hIO), we confirmed that L. plantarum DS0709 Sup exhibited no toxicity. Furthermore, in a 3D spheroid model mimicking in vivo conditions, L. plantarum DS0709 Sup showed similar apoptosis induction and growth-inhibitory effects as in 2D cultures. Thus, these findings suggest that L. plantarum DS0709 has the potential to be developed into a novel microbiome-based therapeutic agent for CRC, offering anti-cancer efficacy without side effects.
在结直肠癌(CRC)的治疗中,采用了多种方法,包括化疗(5-FU、伊立替康和奥沙利铂)、靶向治疗(VEGF抑制剂)和免疫治疗(PD-1/ PD-L1抑制剂)。然而,由于其副作用和有限的疗效,需要更有效的新治疗策略。在这项研究中,我们鉴定了从婴儿粪便中分离的植物乳杆菌DS0709对结直肠癌的抗癌作用。L. plantarum DS0709上清液(Sup)通过诱导凋亡抑制CRC细胞系(HCT116和SNUC5)的生长。此外,使用人类ipsc衍生的肠道类器官(hIO),我们证实L. plantarum DS0709 Sup没有毒性。此外,在模拟体内条件的三维球体模型中,L. plantarum DS0709 Sup显示出与2D培养相似的细胞凋亡诱导和生长抑制作用。因此,这些研究结果表明,L. plantarum DS0709有潜力发展成为一种新的基于微生物组的结直肠癌治疗剂,具有抗癌效果且无副作用。
期刊介绍:
The Journal of Microbiology and Biotechnology (JMB) is a monthly international journal devoted to the advancement and dissemination of scientific knowledge pertaining to microbiology, biotechnology, and related academic disciplines. It covers various scientific and technological aspects of Molecular and Cellular Microbiology, Environmental Microbiology and Biotechnology, Food Biotechnology, and Biotechnology and Bioengineering (subcategories are listed below). Launched in March 1991, the JMB is published by the Korean Society for Microbiology and Biotechnology (KMB) and distributed worldwide.